Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
Open label, phase I-II study to evaluate the safety and activity of intratumoral urelumab
combined with systemic nivolumab in patients with advanced solid tumors. Serial tumor and
blood samples will be obtained during the study to characterize the changes induced by
treatment in the tumor microenvironment, as well as predictive biomarkers of response.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra